EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preferences for (Dis)Continuing Growth Hormone Treatment at Mid-Puberty in Patients with Transient Idiopathic Isolated Growth Hormone Deficiency: A Qualitative Analysis

Joeri Vliegenthart, Iris Vernooij, Eric J E van der Hijden, Stefan Schuiling, Edmond H H M Rings, Erica L T van den Akker, Danielle C M van der Kaay

Hormone Research in Paediatrics · 28.04.2026 · 1-8

DOI: 10.1159/000552013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 28.04.2026. Verfasst von Joeri Vliegenthart und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, Department of Pediatrics, Erasmus University Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherla…. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The SEENEZ GH trial found no difference in near adult height (NAH) between patients with isolated idiopathic growth hormone deficiency (IIGHD) who continued or discontinued recombinant human growth hormone (rhGH) at mid-puberty after a sufficient GH retest. These findings support revision of the current guideline to recommend rhGH discontinuation for patients with a sufficient mid-pubertal retest result. To enable successful adaptation, insight into stakeholder preferences, perceived (dis)advantages, and factors influencing guideline implementation is crucial.

Methods

A qualitative study was conducted based on 25 interviews involving 26 participants, including patients with transient IIGHD, their parents, healthcare professionals, and organizational stakeholders. Participants were asked to assume there was no clinical difference between (dis)continuing rhGH. Interviews combined a structured impact analysis tool with open-ended questions.

Results

Patients and parents generally preferred rhGH continuation, mainly for reassurance and reduced uncertainty. Patients valued discontinuation for reducing injection-related pain, whereas continuation aligned with personal treatment goals. Parents perceived rhGH continuation as reducing uncertainty. Healthcare professionals and organizational stakeholders favored discontinuation, citing cost-effectiveness, reduced workload, and ethical concerns about overtreatment; lower healthcare costs were the main perceived advantage. Facilitators for guideline revision included positive communication, clear and timely information, and sufficient implementation resources. Barriers included old habits among clinicians, limited awareness of new evidence among stakeholders, and a lack of strong drivers for change.

Conclusion

Patients and parents favored continuing rhGH, whereas professionals and organizational stakeholders preferred discontinuation. Given comparable NAH outcomes after a sufficient mid-pubertal GH retest, successful guideline revision requires clear communication, adequate resources, and involvement of patients and parents.

Schlagwörter

Stichwörter der Autor:innen

Growth hormone deficiencyIdiopathic isolated growth hormone deficiencyImplementationInterviewMid-pubertyPubertyQualitativeWithdrawal

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology, Department of Pediatrics, Erasmus University Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands, j.vliegenthart@erasmusmc.nl.
  • Division of Pediatric Endocrinology, Department of Pediatrics, Erasmus University Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Zilveren Kruis Zorgverzekeringen, Leiden, The Netherlands.
  • Zorgevaluatie en Gepast Gebruik, Diemen, The Netherlands.
  • Department of Pediatrics, Erasmus University Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands.

Zitieren

APA

Vliegenthart, J., Vernooij, I., van der Hijden, E. J. E., Schuiling, S., Rings, E. H. H. M., van den Akker, E. L. T., & van der Kaay, D. C. M. (2026). Preferences for (Dis)Continuing Growth Hormone Treatment at Mid-Puberty in Patients with Transient Idiopathic Isolated Growth Hormone Deficiency: A Qualitative Analysis. Hormone Research in Paediatrics, 1-8. https://doi.org/10.1159/000552013

Vancouver

Vliegenthart J, Vernooij I, van der Hijden EJE, Schuiling S, Rings EHHM, van den Akker ELT, et al. Preferences for (Dis)Continuing Growth Hormone Treatment at Mid-Puberty in Patients with Transient Idiopathic Isolated Growth Hormone Deficiency: A Qualitative Analysis. Hormone Research in Paediatrics. 2026:1-8. doi:10.1159/000552013

BibTeX
@article{Vliegenthart2026,
  author = {Vliegenthart, Joeri and Vernooij, Iris and van der Hijden, Eric J E and Schuiling, Stefan and Rings, Edmond H H M and van den Akker, Erica L T and van der Kaay, Danielle C M},
  title = {Preferences for (Dis)Continuing Growth Hormone Treatment at Mid-Puberty in Patients with Transient Idiopathic Isolated Growth Hormone Deficiency: A Qualitative Analysis},
  journal = {Hormone Research in Paediatrics},
  year = {2026},
  pages = {1--8},
  doi = {10.1159/000552013}
}
Kostenlos starten →